April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Preliminary results of aflibercept in treatment naïve choroidal neovascularization of neovascular age-related macular degeneration
Author Affiliations & Notes
  • Sandrine A Zweifel
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Christoph Amstutz
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Johannes Fleischhauer
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Malaika Kurz-Levin
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Daniel Barthelmes
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Footnotes
    Commercial Relationships Sandrine Zweifel, Bayer (C); Christoph Amstutz, None; Johannes Fleischhauer, None; Malaika Kurz-Levin, None; Daniel Barthelmes, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3942. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandrine A Zweifel, Christoph Amstutz, Johannes Fleischhauer, Malaika Kurz-Levin, Daniel Barthelmes; Preliminary results of aflibercept in treatment naïve choroidal neovascularization of neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3942.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the early response of aflibercept as first-line treatment in patients with newly diagnosed choroidal neovascularization (CNV) in age-related macular degeneration in a clinical setting.

Methods: Analysis of 38 eyes (35 patients, 28 female, 7 male) with treatment naïve active CNV. Lesion activity was determined based on fluorescein angiography, clinical and optical coherence tomography (OCT) findings including the presence of sub-, intraretinal fluid, retinal pigment epithelial (RPE) detachment and hemorrhage. LogMAR charts were used for testing best corrected or best available visual acuity (BCVA). Treatment response was evaluated based on change in BCVA and lesion activity.

Results: Classic or predominantly classic CNV was diagnosed in 8 eyes (21.1%), occult or minimally classic in 22 eyes (57.9%), retinal angiomatous proliferation in 5 eyes (13.2%) and polypoidal choroidal vasculopathy in 3 eyes (7.9%). Lesion activity was evaluated as unchanged in only one eye. In all other eyes a definite treatment response was observed with complete resolution of fluid in 20 eyes after a single injection. Three eyes did not show improved sub-RPE fluid with smaller pigment epithelial detachments. A rip of the RPE was seen in 3 eyes. All patients maintained vision, 7 patients (7 eyes) gained > 15 letters from baseline to month 2 folllow-up, of which 4 reached this level of visual acuity after one injection. The visual acuity gains were maintained in this study through 6 months for the eyes with longer follow-up.

Conclusions: There seems to be a rapid treatment response to aflibercept independent of the underlying CNV. Aflibercept may be beneficial even in eyes with large pigment epithelial detachments due to exudative AMD.

Keywords: 688 retina • 412 age-related macular degeneration • 609 neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×